Systemic Immune-Inflammation Index is Associated with Cerebral Small Vessel Disease Burden and Cognitive Impairment
Yining Xiao,Zhenjie Teng,Jing Xu,Qianqian Qi,Tianyuan Guan,Xin Jiang,Huifang Chen,Xiaohua Xie,Yanhong Dong,Peiyuan Lv
DOI: https://doi.org/10.2147/NDT.S401098
IF: 2.989
2023-02-22
Neuropsychiatric Disease and Treatment
Abstract:Yining Xiao, 1– 3 Zhenjie Teng, 1– 3 Jing Xu, 2, 3 Qianqian Qi, 2 Tianyuan Guan, 1, 2 Xin Jiang, 2, 3 Huifang Chen, 2 Xiaohua Xie, 2 Yanhong Dong, 2, 3 Peiyuan Lv 1– 3 1 Department of Neurology, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China; 2 Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China; 3 Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, Hebei, People's Republic of China Correspondence: Peiyuan Lv, Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, 050051, People's Republic of China, Email Objective: This study sought to explore the associations of the systemic immune-inflammation index (SII) with total cerebral small vessel disease (CSVD) burden and cognitive impairment. Methods: We enrolled 201 patients in the retrospective study with complete clinical and laboratory data. The SII was calculated as platelet count × neutrophil count/lymphocyte count. Cognitive function was evaluated by the Mini-Mental State Examination (MMSE). Total CSVD burden was assessed based on magnetic resonance imaging. We performed logistic regression models, Spearman correlation, and mediation analysis to evaluate the associations of SII with CSVD burden and cognitive impairment. Results: After adjustment for confounding factors in the multivariate binary logistic regression model, elevated SII (odds ratio [OR], 3.263; 95% confidence interval [CI], 1.577– 6.752; P = 0.001) or severe CSVD burden (OR, 2.794; 95% CI, 1.342– 5.817; P = 0.006) was significantly associated with the risk of cognitive impairment. Correlation analyses revealed that SII levels were negatively associated with MMSE scores (rs = − 0.391, P < 0.001), and positively associated with the total CSVD burden score (rs = 0.361, P < 0.001). Moreover, SII was significantly related to the severity of the CSVD burden (OR, 2.674; 95% CI, 1.359– 5.263; P = 0.004). The multivariable-adjusted odds ratios (95% CI) in highest tertile versus lowest tertile of SII were 8.947 (3.315– 24.145) for cognitive impairment and 4.945 (2.063– 11.854) for severe CSVD burden, respectively. The effect of higher SII on cognitive impairment development was partly mediated by severe CSVD burden. Conclusion: Elevated SII is associated with severe CSVD burden and cognitive impairment. The mediating role of severe CSVD burden suggests that higher SII may contribute to cognitive impairment through aggravating CSVD burden. Keywords: systemic immune-inflammation index, inflammation, cognitive impairment, cerebral small vessel disease, total burden As life expectancies and the aging population across the world continue to rise, cognitive impairment is a major obstacle to healthy aging. 1,2 Cerebral small vessel disease (CSVD), common in the elderly, has become a primary vascular contributor to cognitive impairment. 3 It contributes to 45% of all dementias, posing a tremendous socioeconomic burden. 4,5 CSVD is a chronic disease caused by various etiologies affecting the small intracerebral arteries and their distal branches, arterioles, capillaries, and small veins. 6 White matter hyperintensity (WMH) and lacunes of presumed vascular origin, cerebral microbleeds (CMBs), and enlarged perivascular space (EPVS) are typical magnetic resonance imaging (MRI) features of the disease. 7 Based on these MRI markers, the total CSVD burden score can serve as a better indicator of the severity of CSVD. 8 It has been demonstrated that total CSVD burden is strongly associated with the development of cognitive impairment. 9 Although many studies have focused on the etiological mechanisms of CSVD, they are not yet clear. Recent studies have found that inflammation is strongly associated with CSVD. 10 Recently, the systemic immune-inflammation index (SII) has been proposed as a relatively new systemic inflammatory biomarker. SII is calculated using neutrophil, lymphocyte, and platelet counts in the peripheral blood, more comprehensively reflecting the systemic immune response and inflammatory status. 11,12 Previous studies have revealed that SII has a very high prognostic value in various malignant tumors 13,14 and are associated with poor outcomes in cerebrovascular, 15 cardiovascular 16 and autoimmune diseases. 17 We were particularly interested in its positive correlations with basal ganglia EPVS (BG-EPVS) and modified WMH burden. 18 In -Abstract Truncated-
psychiatry,clinical neurology